Allspring Global Investments Holdings LLC Purchases 167,471 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Allspring Global Investments Holdings LLC lifted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 283.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 226,524 shares of the company’s stock after acquiring an additional 167,471 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.46% of Amphastar Pharmaceuticals worth $6,365,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in AMPH. Gladius Capital Management LP bought a new position in shares of Amphastar Pharmaceuticals in the second quarter worth $35,000. US Bancorp DE boosted its holdings in shares of Amphastar Pharmaceuticals by 49.5% in the second quarter. US Bancorp DE now owns 2,023 shares of the company’s stock worth $70,000 after acquiring an additional 670 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth $74,000. Nisa Investment Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 22.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,550 shares of the company’s stock worth $89,000 after acquiring an additional 460 shares during the period. Finally, Captrust Financial Advisors boosted its holdings in shares of Amphastar Pharmaceuticals by 114.4% in the first quarter. Captrust Financial Advisors now owns 2,770 shares of the company’s stock worth $99,000 after acquiring an additional 1,478 shares during the period. 61.72% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 2.3 %

NASDAQ AMPH opened at $28.96 on Monday. The stock’s 50-day simple moving average is $28.65 and its two-hundred day simple moving average is $30.69. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.07 and a twelve month high of $44.46. The company has a quick ratio of 2.75, a current ratio of 3.76 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 19.44 and a beta of 0.71.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last released its quarterly earnings results on Monday, November 7th. The company reported $0.32 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.32. Amphastar Pharmaceuticals had a return on equity of 16.48% and a net margin of 15.93%. The business had revenue of $120.13 million for the quarter, compared to the consensus estimate of $126.20 million. Research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 1.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on AMPH shares. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 19th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 25th. Finally, Jefferies Financial Group downgraded Amphastar Pharmaceuticals to a “buy” rating and set a $36.00 price objective on the stock. in a research report on Friday, October 21st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Amphastar Pharmaceuticals Profile

(Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.